High-resolution mass spectrometric metabolite profiling of a novel synthetic designer drug, N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (STS-135), using cryopreserved human hepatocytes and assessment of metabolic stability with human liver microsomes

Drug Testing and Analysis

Volumn 7, Issue 3, 2015, Pages 187-198

  Gandhi, Adarsh S ^a,d   Wohlfarth, Ariane ^a,d   Zhu, Mingshe ^b   Pang, Shaokun ^c   Castaneto, Marisol ^a   Scheidweiler, Karl B ^a   Huestis, Marilyn A ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b BRISTOL MYERS SQUIBB RESEARCH AND DEVELOPMENT   (United States)

^c MDS SCIEX   (Canada)

^d LUNDBECK RESEARCH USA   (United States)

Author keywords

High resolution mass spectrometry; Human hepatocytes; Metabolism; STS 135; Synthetic cannabinoids

Indexed keywords

BIOMOLECULES; CHAINS; DATA MINING; DRUG PRODUCTS; HYDROXYLATION; KETONES; MASS SPECTROMETRY; METABOLITES; PHYSIOLOGY; POLYCYCLIC AROMATIC HYDROCARBONS;

CARBOXAMIDES; HIGH RESOLUTION MASS SPECTROMETRY; HUMAN HEPATOCYTES; HUMAN LIVER MICROSOMES; IN-VITRO; METABOLIC STABILITY; PARENT COMPOUNDS; SIDE-CHAINS; STS-135; SYNTHETIC CANNABINOID;

METABOLISM;

AMIDE; CARBOXYLIC ACID; DESIGNER DRUG; N (ADAMANTAN 1 YL) 1 (5 FLUOROPENTYL) 1H INDOLE 3 CARBOXAMIDE; UNCLASSIFIED DRUG; ADAMANTANE; INDOLE DERIVATIVE; N-(ADAMANTAN-1-YL)-1-(5-FLUOROPENTYL)-1H-INDOLE-3-CARBOXAMIDE;

ARTICLE; CRYOPRESERVATION; DEALKYLATION; DEFLUORINATION; DIHYDROXYLATION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SYNTHESIS; HUMAN; IN VITRO STUDY; INTRINSIC CLEARANCE; LIVER CELL; LIVER CLEARANCE; LIVER MICROSOME; MASS SPECTROMETRY; METABOLISM; OUTCOME ASSESSMENT; PRIORITY JOURNAL; VOLUME OF DISTRIBUTION; ANALOGS AND DERIVATIVES; HYDROXYLATION; OXIDATION REDUCTION REACTION;

ADAMANTANE; CRYOPRESERVATION; DESIGNER DRUGS; HEPATOCYTES; HUMANS; HYDROXYLATION; INDOLES; METABOLIC NETWORKS AND PATHWAYS; MICROSOMES, LIVER; OXIDATION-REDUCTION;

EID: 84924726627     PISSN: 19427603     EISSN: 19427611     Source Type: Journal    
DOI: 10.1002/dta.1662     Document Type: Article

References (51)

1. S. Gibbons. 'Legal highs' - novel and emerging psychoactive drugs: A chemical overview for the toxicologist. Clin. Toxicol. 2012, 50, 15.
2. L. Fattore, W. Fratta. Beyond THC: The new generation of cannabinoid designer drugs. Front Behav. Neurosci. 2011, 5, 60.
3. S. Dresen, N. Ferreiros, M. Putz, F. Westphal, R. Zimmermann, V. Auwarter. Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds. J. Mass Spectrom. 2010, 45, 1186.
4. A.L. Patton, K.C. Chimalakonda, C.L. Moran, K.R. McCain, A. Radominska-Pandya, L.P. James, C. Kokes, J.H. Moran. K2 toxicity: Fatal case of psychiatric complications following AM2201 exposure. J. Forensic Sci. 2013, 58, 1676.
5. C. A. Sannerud. Department of Justice, Drug Enforcement Administration. Schedules of controlled substances: Temporary placement of five synthetic cannabinoids into schedule I (JWH-018, JWH-073, JWH-200, CP-47, 497, CP-47, 497 C8 homologue). Fed. Reg. 2011, 76, 11075. http://www.gpo.gov/fdsys/pkg/FR-2011-03-01/html/2011-4428.htm
6. US Government. Synthetic Drug Abuse Prevention Act of 2012 (S.3187), 2012.
7. J. W. Partridge. Department of Justice, Drug Enforcement Administration. Schedules of controlled substances: Temporary placement of three synthetic cannabinoids into schedule I. Fed. Reg. 2013, 78, 21858. http://www.gpo.gov/fdsys/pkg/FR-2013-04-12/html/2013-08671.htm
8. Center for Substance Abuse Research. Synthetic cannabinoid series. CESAR FAX. 2013, 22, 27.
9. A. Makriyannis, H. Deng. Cannabimimetic indole derivatives. International Patent Application WO 01/28557 A1, 2001.
10. J.L. Wiley, J.A. Marusich, T.W. Lefever, M. Grabenauer, K.N. Moore, B.F. Thomas. Cannabinoids in disguise: Delta9-tetrahydrocannabinol-like effects of tetramethylcyclopropyl ketone indoles. Neuropharmacology 2013, 75, 145.
11. N. Langer, R. Lindigkeit, H.M. Schiebel, L. Ernst, T. Beuerle. Identification and quantification of synthetic cannabinoids in 'spice-like' herbal mixtures: A snapshot of the German situation in the autumn of 2012. Drug Test. Anal. 2013, 6, 59.
12. N. Uchiyama, M. Kawamura, R. Kikura-Hanajiri, Y. Goda. URB-754: A new class of designer drug and 12 synthetic cannabinoids detected in illegal products. Forensic Sci. Int. 2013, 227, 21.
13. S. Kneisel, V. Auwarter, J. Kempf. Analysis of 30 synthetic cannabinoids in oral fluid using liquid chromatography-electrospray ionization tandem mass spectrometry. Drug Test. Anal. 2012, 5, 657.
14. M. Hutter, S. Kneisel, V. Auwarter, M.A. Neukamm. Determination of 22 synthetic cannabinoids in human hair by liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2012, 903, 95.
15. E.G. Yanes, D.P. Lovett. High-throughput bioanalytical method for analysis of synthetic cannabinoid metabolites in urine using salting-out sample preparation and LC-MS/MS. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2012, 909, 42.
16. K.G. Shanks, T. Dahn, A.R. Terrell. Detection of JWH-018 and JWH-073 by UPLC-MS-MS in postmortem whole blood casework. J. Anal. Toxicol. 2012, 36, 145.
17. S. Kneisel, M. Speck, B. Moosmann, T.M. Corneillie, N.G. Butlin, V. Auwarter. LC/ESI-MS/MS method for quantification of 28 synthetic cannabinoids in neat oral fluid and its application to preliminary studies on their detection windows. Anal. Bioanal. Chem. 2013, 405, 4691.
18. A. Wohlfarth, K.B. Scheidweiler, X. Chen, H.F. Liu, M.A. Huestis. Qualitative confirmation of 9 synthetic cannabinoids and 20 metabolites in human urine using LC-MS/MS and library search. Anal. Chem. 2013, 85, 3730.
19. A.D. de Jager, J.V. Warner, M. Henman, W. Ferguson, A. Hall. LC-MS/MS method for the quantitation of metabolites of eight commonly-used synthetic cannabinoids in human urine--an Australian perspective. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2012, 897, 22.
20. M. Hutter, S. Broecker, S. Kneisel, V. Auwarter. Identification of the major urinary metabolites in man of seven synthetic cannabinoids of the aminoalkylindole type present as adulterants in 'herbal mixtures' using LC-MS/MS techniques. J. Mass Spectrom. 2012, 47, 54.
21. T. Sobolevsky, I. Prasolov, G. Rodchenkov. Detection of JWH-018 metabolites in smoking mixture post-administration urine. Forensic Sci. Int. 2010, 200, 141.
22. K.C. Chimalakonda, C.L. Moran, P.D. Kennedy, G.W. Endres, A. Uzieblo, P.J. Dobrowolski, E.K. Fifer, J. Lapoint, L.S. Nelson, R.S. Hoffman, L.P. James, A. Radominska-Pandya, J.H. Moran. Solid-phase extraction and quantitative measurement of omega and omega-1 metabolites of JWH-018 and JWH-073 in human urine. Anal. Chem. 2011, 83, 6381.
23. K.C. Chimalakonda, K.A. Seely, S.M. Bratton, L.K. Brents, C.L. Moran, G.W. Endres, L.P. James, P.F. Hollenberg, P.L. Prather, A. Radominska-Pandya, J.H. Moran. Cytochrome p450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/spice: identification of novel cannabinoid receptor ligands. Drug Metab. Dispos. 2012, 40, 2174.
24. A. Grigoryev, S. Savchuk, A. Melnik, N. Moskaleva, J. Dzhurko, M. Ershov, A. Nosyrev, A. Vedenin, B. Izotov, I. Zabirova, V. Rozhanets. Chromatography-mass spectrometry studies on the metabolism of synthetic cannabinoids JWH-018 and JWH-073, psychoactive components of smoking mixtures. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2011, 879, 1126.
25. C.L. Moran, V.H. Le, K.C. Chimalakonda, A.L. Smedley, F.D. Lackey, S.N. Owen, P.D. Kennedy, G.W. Endres, F.L. Ciske, J.B. Kramer, A.M. Kornilov, L.D. Bratton, P.J. Dobrowolski, W.D. Wessinger, W.E. Fantegrossi, P.L. Prather, L.P. James, A. Radominska-Pandya, J.H. Moran. Quantitative measurement of JWH-018 and JWH-073 metabolites excreted in human urine. Anal. Chem. 2011, 83, 4228.
26. N. De Brabanter, S. Esposito, E. Tudela, L. Lootens, P. Meuleman, G. Leroux-Roels, K. Deventer, P. Van Eenoo. In vivo and in vitro metabolism of the synthetic cannabinoid JWH-200. Rapid Commun. Mass Spectrom. 2013, 27, 2115.
27. A. Grigoryev, A. Melnik, S. Savchuk, A. Simonov, V. Rozhanets. Gas and liquid chromatography-mass spectrometry studies on the metabolism of the synthetic phenylacetylindole cannabimimetic JWH-250, the psychoactive component of smoking mixtures. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2011, 879, 2519.
28. A. Grigoryev, P. Kavanagh, A. Melnik. The detection of the urinary metabolites of 1-[(5-fluoropentyl)-1H-indol-3-yl]-(2-iodophenyl)methanone (AM-694), a high affinity cannabimimetic, by gas chromatography - mass spectrometry. Drug Test. Anal. 2012, 5, 110.
29. T. Sobolevsky, I. Prasolov, G. Rodchenkov. Detection of urinary metabolites of AM-2201 and UR-144, two novel synthetic cannabinoids. Drug Test. Anal. 2012, 4, 745.
30. M. Hutter, B. Moosmann, S. Kneisel, V. Auwarter. Characteristics of the designer drug and synthetic cannabinoid receptor agonist AM-2201 regarding its chemistry and metabolism. J. Mass Spectrom. 2013, 48, 885.
31. P. Kavanagh, A. Grigoryev, A. Melnik, A. Simonov. The identification of the urinary metabolites of 3-(4-methoxybenzoyl)-1-pentylindole (RCS-4), a novel cannabimimetic, by gas chromatography-mass spectrometry. J. Anal. Toxicol. 2012, 36, 303.
32. A. Wohlfarth, S. Pang, M. Zhu, A.S. Gandhi, K.B. Scheidweiler, M.A. Huestis. Metabolism of RCS-8, a synthetic cannabinoid with cyclohexyl structure, in human hepatocytes by high-resolution mass spectrometry. Bioanalysis 2014, in press.
33. A. Grigoryev, P. Kavanagh, A. Melnik. The detection of the urinary metabolites of 3-[(adamantan-1-yl)carbonyl]-1-pentylindole (AB-001), a novel cannabimimetic, by gas chromatography-mass spectrometry. Drug Test. Anal. 2012, 4, 519.
34. A. Grigoryev, P. Kavanagh, A. Melnik, S. Savchuk, A. Simonov. Gas and liquid chromatography-mass spectrometry detection of the urinary metabolites of UR-144 and its major pyrolysis product. J. Anal. Toxicol. 2013, 37, 265.
35. A.S. Gandhi, M. Zhu, S. Pang, A. Wohlfarth, K.B. Scheidweiler, H.F. Liu, M.A. Huestis. First characterization of AKB-48 metabolism, a novel synthetic cannabinoid, using human hepatocytes and high-resolution mass spectrometry. AAPS J. 2013, 15, 1091.
36. A. Wohlfarth, S. Pang, M. Zhu, A.S. Gandhi, K.B. Scheidweiler, H.-f. Liu, M.A. Huestis. First metabolic profile of XLR-11, a novel synthetic cannabinoid, obtained by using human hepatocytes and high-resolution mass spectrometry. Clin. Chem. 2013, 59, 1638.
37. A. Wohlfarth, A.S. Gandhi, S. Pang, M. Zhu, K.B. Scheidweiler, M.A. Huestis. Metabolism of synthetic cannabinoids PB-22 and its 5-fluoro analog, 5F-PB-22, by human hepatocyte incubation and high-resolution mass spectrometry. Anal. Bioanal. Chem. 2014, 406, 1763.
38. S.L. Thornton, C. Wood, M.W. Friesen, R.R. Gerona. Synthetic cannabinoid use associated with acute kidney injury. Clin. Toxicol. 2013, 51, 189.
39. T. Murphy. Acute kidney injury associated with synthetic cannabinoid use - multiple states, 2012. Morbidity and Mortality Weekly Report of the Centers for Disease Control and Prevention. CDC, Washington DC, USA, 2013, 62.
40. G.K. Bhanushali, G. Jain, H. Fatima, L.J. Leisch, D. Thornley-Brown. AKI associated with synthetic cannabinoids: a case series. Clin. J. Am. Soc. Nephrol. 2013, 8, 523.
41. A.R. Winstock, M.J. Barratt. The 12-month prevalence and nature of adverse experiences resulting in emergency medical presentations associated with the use of synthetic cannabinoid products. Hum. Psychopharm. Clin. 2013, 28, 390.
42. A. Mir, A. Obafemi, A. Young, C. Kane. Myocardial infarction associated with use of the synthetic cannabinoid K2. Pediatrics 2011, 128, 1622.
43. K.A. Seely, J. Lapoint, J.H. Moran, L. Fattore. Spice drugs are more than harmless herbal blends: A review of the pharmacology and toxicology of synthetic cannabinoids. Prog. Neuro-Psychop. 2012, 39, 234.
44. L.K. Brents, A. Gallus-Zawada, A. Radominska-Pandya, T. Vasiljevik, T.E. Prisinzano, W.E. Fantegrossi, J.H. Moran, P.L. Prather. Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity. Biochem. Pharmacol. 2012, 83, 952.
45. M. Rajasekaran, L.K. Brents, L.N. Franks, J.H. Moran, P.L. Prather. Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors. Toxicol. Appl. Pharm. 2013, 269, 100.
46. P. Baranczewski, A. Stanczak, K. Sundberg, R. Svensson, A. Wallin, J. Jansson, P. Garberg, H. Postlind. Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development. Pharmacol. Rep. 2006, 58, 453.
47. C.A. McNaney, D.M. Drexler, S.Y. Hnatyshyn, T.A. Zvyaga, J.O. Knipe, J.V. Belcastro, M. Sanders. An automated liquid chromatography-mass spectrometry process to determine metabolic stability half-life and intrinsic clearance of drug candidates by substrate depletion. Assay Drug Dev. Technol. 2008, 6, 121.
48. A. Wintermeyer, I. Moller, M. Thevis, M. Jubner, J. Beike, M.A. Rothschild, K. Bender. In vitro phase I metabolism of the synthetic cannabimimetic JWH-018. Anal. Bioanal. Chem. 2010, 398, 2141.
49. K.A. Seely, L.K. Brents, A. Radominska-Pandya, G.W. Endres, G.S. Keyes, J.H. Moran, P.L. Prather. A major glucuronidated metabolite of JWH-018 is a neutral antagonist at CB1 receptors. Chem. Res. Toxicol. 2012, 25, 825.
50. K.C. Chimalakonda, S.M. Bratton, V.H. Le, K.H. Yiew, A. Dineva, C.L. Moran, L.P. James, J.H. Moran, A. Radominska-Pandya. Conjugation of synthetic cannabinoids JWH-018 and JWH-073, metabolites by human UDP-glucuronosyltransferases. Drug Metab. Dispos. 2011, 39, 1967.
51. T. Lavé, S. Dupin, C. Schmitt, B. Valles, G. Ubeaud, R.C. Chou, D. Jaeck, P. Coassolo. The use of human hepatocytes to select compounds based on their expected hepatic extraction ratios in humans. Pharm. Res. 1997, 14, 152.